Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
Active, enrolledNAResults postedLast updated 3 March 2026
What this trial tests
NA trial testing Active Comparator: Active tDCS and Active TUS in Parkinson Disease in 40 participants. Participants enrolled and being followed up; not accepting new ones.
Adults 40 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Improvement in Unified Parkinson's Disease Rating Scale (UPDRS) Part IIIPrimary· Change from baseline to Day 14 (end of stimulation treatment).
Motor function was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III - Motor Examination, which measures tremor, rigidity, bradykinesia, postural instability, and gait.
Scores range from 0 to 108, where higher scores indicate worse motor impairment (i.e., lower scores represent better motor function).
Group
Value
95% CI
Active tDCS and Active TUS
4.42
± 0.42
Sham TDCS and Sham TUS
0.12
± 0.43
Adverse events — posted to ClinicalTrials.gov
Time frame: 14 weeks..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This trial aims to understand the mechanism and to test whether transcranial direct current stimulation (tDCS) combined with transcranial ultrasound (TUS) (tDCS+TUS) combined with physical therapy (PT) will induce significant therapeutic effects in postural instability in Parkinson's disease (PT) patients. The investigators designed a double-blinded, placebo controlled, randomized study to investigate the effects of 2 weeks of TDCS+TUS on postural instability in PD patients receiving PT. (Followed by biweekly sessions for 2 more weeks in Phase II)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other Spaulding Rehabilitation Hospital trials
Trials by the same sponsor.
NCT04940403 — BurtVision™ for Arm Rehabilitation in Chronic Stroke Survivors:
· NA
· not yet recruiting
NCT06193317 — Effects of taVNS on Fibromyalgia Pain
· NA
· not yet recruiting
NCT07483320 — Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy
· NA
· not yet recruiting
NCT06797154 — A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors
· NA
· recruiting
NCT06826781 — Evaluating Q-Collar Effects on Brain Blood Flow Control During Exercise
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spaulding Rehabilitation Hospital
Last refreshed: 3 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03981055.